中国临床药理学杂志2025，Vol.41Issue(22)：3277-3283,7.DOI:10.13699/j.cnki.1001-6821.2025.22.019
新型多黏菌素衍生物的研究进展
Research progress of novel polymyxin derivatives
摘要
Abstract
Polymyxin's clinical application is limited by its significant nephrotoxicity,complex pharmacokinetic and pharmacodynamic characteristics,and the growing issue of bacterial resistance.This systematic review summarizes research progress on three novel polymyxin derivatives:SPR206,QPX9003,and MRX-8.Through structural design,these compounds retain potent antimicrobial activity while reducing nephrotoxicity and improving PK/PD profiles.Preclinical studies and preliminary clinical trials demonstrate broad-spectrum antimicrobial activity against multidrug-resistant Gram-negative bacteria,along with promising efficacy in models such as pulmonary infections.Although these candidate drugs are still undergoing clinical trials,they show potential to become alternatives to existing polymyxin therapies.关键词
多黏菌素/革兰阴性菌/碳青霉烯耐药/SPR206/QPX9003/MRX-8Key words
polymyxin/Gram-negative bacteria/carbapenem resistance/SPR206/QPX9003/MRX-8分类
医药卫生引用本文复制引用
刘世卓,田泽萱,马颖超,杨秀岭..新型多黏菌素衍生物的研究进展[J].中国临床药理学杂志,2025,41(22):3277-3283,7.基金项目
河北省医学适用技术跟踪项目拟推荐基金资助项目(GZ2024039),河北省医学科学研究课题基金资助项目(No.20210257) （GZ2024039）
